In addition, intravenous injection or overexpression of tissue kallikrein (able to generate kallidin, a bradykinin analog, after cleavage of low-molecular kininogen) has beneficial effects in stroke, which are dependent on B2R activation (54, 55). The gene discussed is KNG1; the disease is stroke disorder.